Symbolbild · KI-generiert
Nuvectis Pharma, Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Nuvectis Pharma, Inc. | NVCT | NASDAQ | 678 Mio. USD |
| Rigel Pharmaceuticals, Inc. | RIGL | NASDAQ | 681 Mio. USD |
| Climb Bio, Inc. | CLYM | NASDAQ | 681 Mio. USD |
| CytomX Therapeutics, Inc. | CTMX | NASDAQ | 675 Mio. USD |
| CeriBell, Inc. | CBLL | NASDAQ | 671 Mio. USD |
| Knight Therapeutics Inc. | GUD | TSX | 689 Mio. USD |
| Enghouse Systems Limited | ENGH | TSX | 663 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.